Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
August 20 2024 - 7:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the
appointment of Michael Parks as Vice President of Investor and
Public Relations. Mr. Parks brings nearly 30 years of investor
relations and corporate communications experience working globally
within the biopharmaceutical and healthcare industries. He will
oversee corporate, executive, and digital communications, investor
relations, thought leadership, and branding for the Company. Atossa
is a clinical stage biopharmaceutical company developing innovative
medicines in areas of significant unmet medical need in oncology
with a focus on breast cancer.
“We are excited to welcome Michael to Atossa.
Michael is a highly seasoned corporate communications professional
with experience across healthcare companies of all sizes and stages
of development,” said Steven Quay, M.D., Ph.D., President and Chief
Executive Officer of Atossa. “His extensive experience and
multidisciplined approach to communications will serve Atossa well
in advancing the story of the immense potential of the
(Z)-endoxifen platform for patients and translating this
opportunity into value for investors and other stakeholders.”
Prior to joining Atossa, Mr. Parks was Vice
President of Investor Relations at both PAVmed, a diversified
commercial-stage medical technology company operating in the
medical device, diagnostics, and digital health sectors; and its
publicly traded subsidiary, Lucid Diagnostics, a commercial-stage,
cancer prevention medical diagnostics company. Previously, Mr.
Parks led corporate communications and public affairs efforts at
Liquidia Corporation after serving more than a decade as the
Founder and President of Pitch360, a consulting firm which provided
a full spectrum of investor relations, corporate communications and
public affairs services to private and small-cap biopharmaceutical
companies. Earlier in his career he served as the Vice President of
Corporate Communications at Centocor, a Johnson & Johnson
Company, and held roles of increasing responsibility at Pfizer,
Pharmacia, and Searle Pharmaceuticals.
“I am thrilled to join Atossa at such a pivotal
time in the company’s history,” said Mr. Parks. “Atossa’s
commitment to advancing innovative therapies in oncology,
particularly in breast cancer, aligns perfectly with my passion for
communicating impactful stories to the healthcare, investor, and
patient communities. I look forward to joining this dedicated team
on this journey and continue building value and awareness among
Atossa’s multiple stakeholders.”
About Atossa TherapeuticsAtossa
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing innovative medicines in areas of significant unmet
medical need in oncology with a current focus on breast cancer and
lung injury caused by cancer treatments. For more information,
please visit www.atossatherapeutics.com.
Contact:
Michael Parks VP, Investor and Public
Relations484-356-7105michael.parks@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2023 to Aug 2024